Filtered By:
Drug: Proton Pump Inhibitors PPIs

This page shows you your search results in order of relevance. This is page number 10.

Order by Relevance | Date

Total 238 results found since Jan 2013.

Impact of Proton Pump Inhibitor Therapy on the Efficacy of Clopidogrel in the CAPRIE and CREDO Trials Coronary Heart Disease
Conclusions In CREDO, the efficacy of clopidogrel was not significantly affected by PPI use. However, in CAPRIE, clopidogrel was beneficial to non-PPI users while apparently harmful to PPI users. Whether this negative interaction is clinically important for patients receiving clopidogrel without aspirin needs further study.
Source: JAHA:Journal of the American Heart Association - January 15, 2013 Category: Cardiology Authors: Dunn, S. P., Steinhubl, S. R., Bauer, D., Charnigo, R. J., Berger, P. B., Topol, E. J. Tags: Coronary Heart Disease Source Type: research

Cardioprotective effects and gastrointestinal risks of aspirin: Maintaining the delicate balance
Publication date: 6 September 2004 Source:The American Journal of Medicine Supplements, Volume 117, Issue 5, Supplement 1 Author(s): Michael B. Kimmey Aspirin is a very useful medication for the prevention of cardiovascular thrombotic events in patients with or those at risk for cardiovascular disease (CVD). Aspirin, however, carries an increased risk for gastrointestinal (GI) injury (e.g., ulceration) and its complications (e.g., hemorrhage), which may be caused by its antiplatelet and gastric mucosal effects. In those with established CVD, aspirin use has been documented to decrease the risk of a first myocardial infar...
Source: The American Journal of Medicine Supplements - November 6, 2014 Category: Drugs & Pharmacology Source Type: research

Link between indigestion drugs and dementia 'inconclusive'
Conclusion This study found people taking PPIs had a 44% higher risk of developing dementia in a seven-year period compared with those not taking the drugs. However, it's not accurate to say this was down to the PPIs – the study couldn't prove this, and there are many possible explanations. For a start, the groups weren't very similar. Those taking PPIs had poorer health, and were more likely to be taking a number of medicines and have conditions linked to a higher risk of dementia, such as diabetes and heart disease. After taking these factors into account in the analysis, the link between PPIs and dementia reduc...
Source: NHS News Feed - February 16, 2016 Category: Consumer Health News Tags: Medication Neurology Older people Source Type: news

A Prospective, Randomized, Open-Label Study to Evaluate Two Management Strategies for Gastrointestinal Symptoms in Patients Newly on Treatment with Dabigatran
ConclusionThe majority of patients enrolled either did not experience GIS at all, or their GIS resolved using either one individually, or a combination of the two strategies described.Trial registrationhttp://www.ClinicalTrials.gov identifier: NCT01493557.
Source: Cardiology and Therapy - October 4, 2016 Category: Cardiology Source Type: research

Morning Report: Aspirin & CVD, PPIs & Stroke, Magic Mushrooms Morning Report: Aspirin & CVD, PPIs & Stroke, Magic Mushrooms
Dr Arefa Cassoobhoy highlights some of this week ' s most important medical news, including aspirin to prevent CVD in type 2 diabetes, another risk from PPIs, and a novel use for magic mushrooms.Medscape Internal Medicine
Source: Medscape Internal Medicine Headlines - December 9, 2016 Category: Internal Medicine Tags: Internal Medicine Commentary Source Type: news

Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular OutcoMes for People Using Anticoagulation StrategieS (COMPASS) Trial
Conclusion COMPASS will provide information on the efficacy and safety of rivaroxaban, alone or in combination with aspirin, in the long-term management of patients with stable CAD or PAD, and on the efficacy and safety of pantoprazole in preventing upper GI complications in patients receiving antithrombotic therapy. Teaser COMPASS is a global randomized controlled trial comparing rivaroxaban 2.5mg twice-daily plus aspirin 100mg once-daily, rivaroxaban 5mg twice-daily, and aspirin 100mg once-daily for prevention of myocardial infarction, stroke, or cardiovascular death in patients with stable coronary or peripheral artery ...
Source: Canadian Journal of Cardiology - June 8, 2017 Category: Cardiology Source Type: research

Bleeding risk with long-term aspirin increases substantially with age
GPs should prescribe PPIs to elderly people to cut risk, researchers suggest Related items fromOnMedica Benefits of taking aspirin highest in women aged 65 plus Aspirin boosts cancer immunotherapy, study shows Long-term aspirin use linked to lower risk of gastrointestinal tract cancers Aspirin after mini-stroke reduces risk of major stroke
Source: OnMedica Latest News - June 14, 2017 Category: UK Health Source Type: news

Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study
Publication date: Available online 13 June 2017 Source:The Lancet Author(s): Linxin Li, Olivia C Geraghty, Ziyah Mehta, Peter M Rothwell Background Lifelong antiplatelet treatment is recommended after ischaemic vascular events, on the basis of trials done mainly in patients younger than 75 years. Upper gastrointestinal bleeding is a serious complication, but had low case fatality in trials of aspirin and is not generally thought to cause long-term disability. Consequently, although co-prescription of proton-pump inhibitors (PPIs) reduces upper gastrointestinal bleeds by 70–90%, uptake is low and guidelines are conflicti...
Source: The Lancet - June 15, 2017 Category: General Medicine Source Type: research

Establishing Therapeutic Equivalence of Complex Pharmaceuticals: The Case of Dabigatran
Publication date: Available online 5 June 2018 Source:Canadian Journal of Cardiology Author(s): Jeffrey Weitz, Karen M. Earl, Kori Leblanc, William Semchuk, Fakhreddin Jamali Dabigatran is widely used for stroke prevention in atrial fibrillation. Dabigatran is no longer patent protected in Canada and 2 generic formulations were recently approved by Health Canada. Branded dabigatran utilizes a complex formulation to maintain the acidic microenvironment required for maximal absorption. Consequently, food does not influence its bioavailability and the efficacy and safety of dabigatran are similar with or without concomitant ...
Source: Canadian Journal of Cardiology - June 6, 2018 Category: Cardiology Source Type: research

Anticoagulation in Atherosclerotic Disease.
Abstract The prevention of atherothrombotic events is an essential therapeutic goal in the treatment of patients with arteriosclerotic diseases. After plaque rupture, a rapidly growing thrombus can lead to acute vascular occlusion and thus heart attack, stroke or limb ischaemia. The acute therapy combines anticoagulation and platelet inhibition. However, the only available therapy so far in the primary and secondary prevention of stable patients is the platelet inhibitors aspirin and clopidogrel. Despite the use of antiplatelet therapies, including aspirin and P2Y12-receptor antagonists, some patients with artery ...
Source: Hamostaseologie - October 17, 2018 Category: Hematology Authors: Al Said S, Bode C, Duerschmied D Tags: Hamostaseologie Source Type: research

Efficacy and safety of clopidogrel only vs. clopidogrel added proton pump inhibitors in the treatment of patients with coronary heart disease after percutaneous coronary intervention: A systematic review and meta-analysis
ConclusionsThe patients in the non-PPI group were observed to be associated with less risk of MACE, myocardial infarction recurrence, stent thrombosis, target vessel revascularization (TVR) and stroke. And the two groups had similar all cause death, cardiovascular death, bleedings events.
Source: IJC Heart and Vasculature - April 2, 2019 Category: Cardiology Source Type: research

Risk of major adverse cardiovascular events for concomitant use of clopidogrel and proton pump inhibitors in patients inheriting CYP2C19 loss-of-function alleles: meta-analysis
Conclusion Patients inheritingCYP2C19 loss-of-function alleles have significantly increased risk of major adverse cardiovascular events when taking clopidogrel and proton pump inhibitors concurrently.
Source: International Journal of Clinical Pharmacy - March 28, 2021 Category: Drugs & Pharmacology Source Type: research

Impact of proton pump inhibitors on mortality and severe esophageal injury after catheter ablation for atrial fibrillation: a nationwide retrospective study using propensity score matching
AbstractStudies on the protective effects of proton pump inhibitors (PPIs) on mortality and severe esophageal injury after catheter ablation for atrial fibrillation are lacking. However, some reports have recommended use of PPIs for prophylaxis against esophageal injury. We investigated the effects of PPIs on mortality and severe esophageal injury after ablation. We retrospectively extracted data for adult in-patients who received catheter ablation with a diagnosis of atrial fibrillation from July 2010 to March 2018. The patients were divided into two groups: with PPI (PPI group) and without PPI (non-PPI group) administrat...
Source: Heart and Vessels - April 30, 2021 Category: Cardiology Source Type: research